Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two Phase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1(212)201-0920 steve.pakola@thrombogenics.com
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to ... today announced the launch of its new genomic data analysis ... American Society of Human Genetics (ASHG) annual meeting in ... and apply for free beta access, visit www.nextcode.com . ... be viewed here . The Exchange: ...
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
Breaking Biology Technology:The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Senetek PLC,(OTC Bulletin Board: SNKTY), a Life Sciences ... science of healthy aging, today,announced that shareholders have approved ... Annual General Meeting of Shareholders held on,December 16, 2008. ... pleased with the results of the voting and we ...
... In a recent customer satisfaction,survey of over 30,000 readers ... by its customers as the "Top Of Class" winner ... who,subscribe to ADVANCE chose bioMerieux over other clinical laboratory ... "reliable,instruments," and "quick response time." , ...
... Senior Director, Commercial Development;Sam Zeller appointed Senior Director, Regulatory ... Mass., Dec. 17 Microbia Precision Engineering, Inc. (Microbia) ... team and bioproduct commercialization capabilities with the appointments of ... Sam Zeller as Senior Director of Regulatory Affairs. , ...
Cached Biology Technology:Senetek PLC Announces 2008 Annual General Meeting Voting Results 2Laboratory Customers Name bioMerieux 'Top Of Class' for Microbiology 2Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts 2Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... In our zest for cleanliness, have we permanently muddied ... from Arizona State University, in collaboration with federal partners,has ... Minnesota, finding widespread evidence of the presence of active ... and rivers. These products are a billion dollar ...
... species could soon follow, according to new research. Scientists have ... team has now carried out the first experiment to prove ... Society journal Biology Letters , the study shows how ... to become extinct. The University of Exeter team believes any ...
... the U.S. Department of Energy,s Ames Laboratory are helping ... tissue structures. The new method opens up new ... for biofuels research and crop genetics. "The ... Ames Laboratory faculty scientist heading up the project, funded ...
Cached Biology News:Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 2Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 3Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 4Study proves that 1 extinction leads to another 2Finding new research frontiers in a single cell 2Finding new research frontiers in a single cell 3
... Genomic Labeling Systems are a high-performance labeling ... DNA samples for array-based Comparative Genomic Hybridization ... labeling formats, the BioPrime Plus Array CGH ... to your genomic labeling needs. Using ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
...
Biology Products: